Oura Eyes September IPO at Over $16 Billion Valuation
Oura targets a September U.S. IPO, seeking up to $3 billion at a valuation above $16 billion as revenue surges and a sleep tracking lawsuit looms.
Summary
Oura, the smart ring maker with offices in San Francisco and Finland and more than 900 employees, reportedly aims to raise up to $3 billion in a U.S. IPO as soon as September 2026 at a valuation above $16 billion. Investors are expected to sell a major stockholding. Oura filed confidentially in May 2026. The target exceeds its $10.9 billion September 2025 valuation, set after an $875 million Series E backed by Fidelity, ICONIQ, Whale Rock and Atreides, alongside earlier investors Dexcom, The Chernin Group, Forerunner Ventures, Coatue and Temasek. Revenue rose from $500 million in 2024 to roughly $1 billion in 2025, and Oura expects nearly $2 billion in 2026. More details will emerge when its S-1 becomes public.
Competition is intensifying. Samsung launched Galaxy Ring in 2024, while Whoop expanded beyond elite athletes and young men into hormone tracking and blood testing for perimenopause and thyroid health, reaching a $10 billion valuation in March 2026. Oura similarly moved beyond biohacking CEOs into mainstream sleep and recovery. A proposed class action filed in San Francisco the week before August 24 alleges Oura misrepresented sleep staging accuracy, arguing exact stages require scalp electrodes and eye sensors in clinical settings. Oura plans to defend itself, says Oura Ring is neither a medical device nor a clinical sleep study substitute, and maintains that independent studies validate its sleep staging against polysomnography, the clinical gold standard.
Positives
- Oura expects nearly $2 billion in 2026 revenue, up from roughly $1 billion in 2025 and $500 million in 2024.
- A September 2026 IPO could raise up to $3 billion and value Oura above $16 billion.
- The $875 million Series E attracted Fidelity, ICONIQ, Whale Rock and Atreides at a $10.9 billion valuation.
- Oura has expanded from biohacking CEOs into the broader sleep and recovery market.
- Independent studies compare Oura sleep staging favorably with polysomnography, according to the company.
Risks & concerns
- A proposed San Francisco class action alleges Oura misled consumers about the accuracy of its sleep staging features.
- Investors are expected to sell a major stockholding in the IPO, adding substantial secondary shares to the offering.
- Samsung Galaxy Ring and the $10 billion Whoop intensify competition in an increasingly crowded wearables market.
- Oura acknowledges its ring is not a medical device or a substitute for a clinical sleep study.
- The public S-1 is not yet available, leaving detailed financial performance and offering terms undisclosed.